CD274 and non-small cell lung carcinoma: In a phase II trial of 42 patients with NSCLC with BM treated with pembrolizumab, intracranial ORR and icDCR was 30% and 40.5%, respectively, with a median duration of response of 5.7 months for patients with PD-L1 expression >1% (108).